Signal: Wegovy cuts cardiovascular risk by 20% for heart disease patients
Novo Nordisk’s blockbuster weight-loss drug Wegovy may reduce the risk of heart attack before the weight loss effects take place,…
Diabetes
-
-
Novo Nordisk to close kidney outcomes trial for Ozempic
Novo Nordisk has announced that it will stop the kidney outcomes trial for the company’s blockbuster drug, Ozempic, even after…
-
Metabolic disorders on Twitter: Diabetes leads mentions in August 2019
Pharmaceutical Technology lists the top tweeted terms on metabolic disorders in August 2019, based in data from Global Data’s Influencer…
